Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 40.92 -6.04% -2.63
ZNTL closed down 0.18 percent on Thursday, March 4, 2021, on 1.15 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical ZNTL trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength -6.04%
50 DMA Resistance Bearish -6.21%
Stochastic Sell Signal Bearish -6.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.21%
Doji - Bearish? Reversal -6.21%
Upper Bollinger Band Walk Strength -6.21%
Overbought Stochastic Strength -6.21%
Upper Bollinger Band Touch Strength -6.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.93%
200 DMA Support Bullish -5.93%
Older End-of-Day Signals for ZNTL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
200 DMA Support about 3 hours ago
20 DMA Support about 3 hours ago
Fell Below 20 DMA about 4 hours ago
Down 10% about 4 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Her2 Molecule Therapeutics Her2/Neu Estrogen Transcription Factors Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders

Is ZNTL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 61.29
52 Week Low 23.25
Average Volume 260,497
200-Day Moving Average 41.68
50-Day Moving Average 44.75
20-Day Moving Average 39.64
10-Day Moving Average 40.61
Average True Range 2.82
ADX 20.94
+DI 24.21
-DI 16.82
Chandelier Exit (Long, 3 ATRs ) 37.01
Chandelier Exit (Short, 3 ATRs ) 42.94
Upper Bollinger Band 44.54
Lower Bollinger Band 34.75
Percent B (%b) 0.9
BandWidth 24.68
MACD Line -0.17
MACD Signal Line -1.22
MACD Histogram 1.0572
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 40.6 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 6.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.50
Resistance 3 (R3) 47.38 45.96 46.84
Resistance 2 (R2) 45.96 44.95 46.01 46.62
Resistance 1 (R1) 44.75 44.33 45.36 44.87 46.40
Pivot Point 43.33 43.33 43.63 43.38 43.33
Support 1 (S1) 42.12 42.32 42.73 42.24 40.70
Support 2 (S2) 40.70 41.70 40.75 40.48
Support 3 (S3) 39.49 40.70 40.26
Support 4 (S4) 39.61